

## **Family Impact of Moderate-to-Severe Atopic Dermatitis in Children Aged <12 years: Results From 732 Patients in the PEDiatric Study in Atopic Dermatitis (PEDISTAD) Observational Study**

Marjolein de Bruin-Weller<sup>1</sup>, Marie L.A. Schuttelaar<sup>2</sup>, Charles W. Lynde<sup>3,4</sup>, Nelson Augusto Rosario Filho<sup>5</sup>, Rajan Gupta<sup>6</sup>, Brad Shumel<sup>7</sup>, Annie Zhang<sup>8</sup>

<sup>1</sup>University Medical Center Utrecht, Utrecht, Netherlands; <sup>2</sup>University of Groningen, Groningen, Netherlands; <sup>3</sup>University of Toronto, Markham, ON, Canada; <sup>4</sup>Lynderm Research, Markham, ON, Canada; <sup>5</sup>Hospital de Clínicas da Universidade Federal do Paraná, Curitiba, Brazil; <sup>6</sup>TechData LLC, King of Prussia, PA, USA; <sup>7</sup>Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA; <sup>8</sup>Sanofi, Cambridge, MA, USA

**Objective:** To describe the real-world family impact of moderate-to-severe atopic dermatitis (AD) in children aged <12 years.

**Methods:** PEDISTAD (NCT03687359) is an ongoing, international, non-interventional study in patients aged <12 years with moderate-to-severe AD inadequately controlled with topical therapies or for whom such therapies are inadvisable. Baseline measures of disease severity reported include Eczema Area and Severity Index (EASI; 0–72) and AD-affected body surface area (BSA). Family impact measures used include Caregiver Global Assessment of Disease (CGAD) and Dermatitis Family Impact (DFI) questionnaire (10 questions, each scored 0 [not at all] to 3 [very much]; 0–30).

**Results:** Among 732 children (52.2% male; mean±SD age 6.2±3.2 years), EASI (mean±SD) was 14.4±10.7 and BSA affected (%), 33.3±21.0. Proportion of caregivers reporting no symptoms/mild, moderate and severe/very severe in CGAD were 24.2%, 42.2%, and 33.6%, respectively. Overall DFI (mean±SD) score was 10.9±7.4, with many caregivers reporting their child's AD had "very much"/"quite a lot" of impact on: expenditure (46.7%), tiredness/exhaustion (40.7%), family sleep (40.7%), caregiver life due to AD treatment (38.3%), emotional distress (37.5%), housework (32.6%), family leisure (25.9%), food preparation/feeding (23.3%), and family relationships (18.4%). Overall DFI scores worsened with increasing AD severity (by EASI/BSA). Results were comparable across age groups (0 to <2, 2 to <6, 6 to <12 years).

**Conclusions:** Caregivers of children with moderate-to-severe AD in PEDISTAD reported a multidimensional impact on caregiver/family life. Family impact also worsened with increasing AD

severity. The impacts on caregivers/family should be considered when making treatment decisions for childhood moderate-to-severe AD.

### **Acknowledgments**

Data first presented at the 80<sup>th</sup> Annual American Academy of Dermatology Meeting (AAD); Mar25-29, 2022. Research sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. Medical writing/editorial assistance was provided by Sandra Dedrick, PhD, of Excerpta Medica, and was funded by Sanofi and Regeneron Pharmaceuticals, Inc., according to the [Good Publication Practice guideline](#).

### **Disclosures**

**de Bruin-Weller M:** Regeneron Pharmaceuticals, Inc., Sanofi – Principal Investigator, advisory board member, consultant; AbbVie, LEO Pharma, Pfizer – Principal Investigator, advisory board member; Arena Pharmaceuticals, Aslan Pharmaceuticals, Eli Lilly, UCB – advisory board member. **Schuttelaar MLA:** AbbVie, Eli Lilly, Galderma, LEO Pharma, Pfizer, Sanofi – advisory board member; AbbVie, Galderma, Novartis, Regeneron Pharmaceuticals, Inc., Sanofi – investigator; Regeneron Pharmaceuticals, Inc. – consultant; Novartis, Sanofi – research grant. **Lynde CW:** AbbVie, GSK, Pfizer, Regeneron Pharmaceuticals, Inc., Sanofi, Sanofi – investigator, consultant, and/or speaker; Glenmark – investigator, consultant. **Rosario Filho NA:** AbbVie, AstraZeneca, Boehringer Ingelheim, Chiesi, Sanofi, Viatrix – investigator, consultant and/or speaker. **Gupta R:** Employee of TechData Service LLC – holds no stock and/or stock options in any pharmaceutical company. **Shumel B:** Regeneron Pharmaceuticals, Inc. – employee and shareholder. **Zhang A:** Sanofi – employee, may hold stock and/or stock options in the company.